• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Consumer Cyclical·688793.SS
Share

Shenzhen Breo Technology Co., Ltd. Stocks

CN¥ 16.27Last Updated 17.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CN¥ 203.32M

CN¥ 16.27
Key Takeaways

Risk factor

High price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Operating from China, Shenzhen Breo Technology Co Ltd is dedicated to the innovation and development of health-focused products. The company's core activities involve the entire spectrum of smart portable massagers, from their initial design and research to manufacturing, sales, and after-sales service. Their product offerings predominantly feature intelligent, compact massage devices tailored for four key areas: the eyes, neck, head, and scalp. These items are primarily marketed under their established proprietary brands, "breo" and "Beijiao" series. The majority of the company's commercial operations are concentrated within the Chinese domestic market.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA, ov

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very favourable
7/7
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

18.07.2026 16:01

Small caps last week: Papa John's doubts, Perfect goes private, LLY-AtaiBeckley deal

18.07.2026 13:01

IBM's Worst Day, SK Hynix's Record Plunge, and the "Earnings Bubble" in AI

18.07.2026 03:31

Meta Is in Talks with Anthropic to Lease Data Centers for $10 Billion — The New York Times

18.07.2026 01:33

U.S. stocks closed lower. Chipmakers had their worst week in more than a year.

18.07.2026 00:58

Adidas won the marketing battle against Nike at the World Cup. Investors took note.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026